Pipeline Overview
Genosco’s current pipeline consists of three assets in the clinical stage, and two assets
in the pre-clinical stage. Our core competence comes from its know-how in generating selective
kinase inhibitor of interest.
in the pre-clinical stage. Our core competence comes from its know-how in generating selective
kinase inhibitor of interest.
(NSCLC) and its metastatic brain cancer, is in clinical phase 3 study. This program is our most
advanced pipeline and has been licensed out to Yuhan Corporation.
purpura (ITP), is in clinical phase 2 study.
program has been licensed out to Yuhan Corporation.
Proprietary Pipeline
Discovery | Lead Opt | Preclinical | Phase I | Phase II | Phase III | |
---|---|---|---|---|---|---|
SKI-O-703(RA) | ||||||
SKI-O-703(ITP) | ||||||
SKI-G-801(AML) | ||||||
ROCK2 Program | ||||||
FGFR2/3 Program |
Collaborative Pipeline
Discovery | Lead Opt | Preclinical | Phase I | Phase II | Phase III | |
---|---|---|---|---|---|---|
Lazertinib:GNS-1480(NSCLC) | ||||||
4th Gen EGFR inhibitor(NSCLC) | ||||||
FGFR4 inhibitor(HCC) |